US FDA approves rimegepant for the preventive treatment of migraine

Rimegepant, an oral CGRP antagonist, is already approved in US for acute treatment of migraine. The licence extension is based on data from a Phase III study showing 75mg every other day decreased monthly migraine days by 4.3 days per month after 3 months of treatment.

Source:

Biospace Inc.